GlassScriptPhysician profile
Jason M Rubin
NPI 1376703090
$389.75
in general payments reported to CMS, 2019-2025
10 companies · $59.61 in 2025
The $59.61 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $31.12 · 2021: $11.97 · 2022: $113 · 2023: $48.88 · 2024: $126 · 2025: $59.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $196 · Education: $37.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $196.28 |
| Education | $37.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $137.99 | 2020-2024 | Darzalex |
| Merck Sharp & Dohme LLC | $59.55 | 2022-2025 | Keytruda, Welireg |
| Daiichi Sankyo INC. | $47.35 | 2024 | Enhertu |
| Genentech USA, INC. | $29.26 | 2024 | Ocrevus Zunovo |
| Pfizer INC. | $27.19 | 2020-2024 | |
| Exelixis INC. | $24.37 | 2025 | Cabometyx |
| Apellis Pharmaceuticals, INC. | $22.88 | 2023 | Empaveli |
| Alexion Pharmaceuticals, INC. | $15.00 | 2024 | Ultomiris |
| Beone Medicines USA, INC. | $14.19 | 2025 | Brukinsa |
| Acrotech Biopharma INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.